Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

被引：0
|
作者：
Carole Dembek
Leigh Ann White
Jayson Quach
Andrea Szkurhan
Nazia Rashid
M. R. Blasco
机构：
[1] Avalere Health,
[2] Biogen Idec,undefined
[3] Dymaxium,undefined
[4] Hospital Universitario Puerta de Hierro,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Multiple sclerosis; Cost-effectiveness; Disease-modifying therapies; Interferon-beta; I1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 362
页数：9
相关论文
共 50 条
  • [1] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Dembek, Carole
    White, Leigh Ann
    Quach, Jayson
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04): : 353 - 362
  • [2] Cost-Effectiveness of Injectable Disease-Modifying Therapies in the Treatment of Multiple Sclerosis
    Quach, Jayson
    Dembek, Carole
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    [J]. NEUROLOGY, 2011, 76 (09) : A474 - A474
  • [3] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [4] Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
    Ali Manouchehrinia
    Cris S. Constantinescu
    [J]. Current Neurology and Neuroscience Reports, 2012, 12 : 592 - 600
  • [5] Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
    Manouchehrinia, Ali
    Constantinescu, Cris S.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (05) : 592 - 600
  • [6] COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE
    Petropoulos, A.
    Cooney, P.
    Patidar, M.
    Gudala, K.
    Tiwari, S.
    Brennan, R.
    Kapsogeorgiou, K.
    Cheilas, G.
    Banhazi, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S80 - S81
  • [7] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [8] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A VS. FIRST LINE INJECTABLE DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Ruiz, L.
    Toro-Diaz, H.
    Cele, C.
    Hernandez, L.
    Harrington, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A723 - A723
  • [9] Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature
    Yamamoto, David
    Campbell, Jonathan D.
    [J]. AUTOIMMUNE DISEASES, 2012, 2012
  • [10] Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
    Simoens, Steven
    [J]. FRONTIERS IN NEUROLOGY, 2022, 13
12345